BRPI1008023A2 - forma de dosagem sólida - Google Patents
forma de dosagem sólidaInfo
- Publication number
- BRPI1008023A2 BRPI1008023A2 BRPI1008023A BRPI1008023A BRPI1008023A2 BR PI1008023 A2 BRPI1008023 A2 BR PI1008023A2 BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A2 BRPI1008023 A2 BR PI1008023A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- solid dosage
- solid
- dosage
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15260809P | 2009-02-13 | 2009-02-13 | |
| PCT/US2010/024127 WO2010093944A2 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1008023A2 true BRPI1008023A2 (pt) | 2016-03-15 |
| BRPI1008023B1 BRPI1008023B1 (pt) | 2019-12-31 |
| BRPI1008023B8 BRPI1008023B8 (pt) | 2023-04-11 |
Family
ID=42335073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008023A BRPI1008023B8 (pt) | 2009-02-13 | 2010-02-12 | Forma de dosagem sólida |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8747901B2 (pt) |
| EP (2) | EP2395979B1 (pt) |
| JP (1) | JP5775464B2 (pt) |
| KR (2) | KR20140016441A (pt) |
| CN (2) | CN102387789A (pt) |
| AU (1) | AU2010213594B2 (pt) |
| BR (1) | BRPI1008023B8 (pt) |
| CA (1) | CA2752048C (pt) |
| CO (1) | CO6361904A2 (pt) |
| CY (2) | CY1119595T1 (pt) |
| DK (2) | DK2395979T3 (pt) |
| EA (1) | EA023652B1 (pt) |
| ES (2) | ES2646816T3 (pt) |
| HK (1) | HK1220130A1 (pt) |
| HR (2) | HRP20171639T1 (pt) |
| HU (2) | HUE044005T2 (pt) |
| IL (1) | IL214258A (pt) |
| LT (2) | LT2395979T (pt) |
| MX (1) | MX2011008344A (pt) |
| MY (1) | MY173715A (pt) |
| NO (1) | NO2395979T3 (pt) |
| NZ (1) | NZ594488A (pt) |
| PL (2) | PL2395979T3 (pt) |
| PT (2) | PT2395979T (pt) |
| SG (1) | SG173601A1 (pt) |
| SI (2) | SI2395979T1 (pt) |
| SM (2) | SMT201900432T1 (pt) |
| TR (1) | TR201909743T4 (pt) |
| WO (1) | WO2010093944A2 (pt) |
| ZA (1) | ZA201105630B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| MX2010011439A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17. |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| SI2395979T1 (sl) | 2009-02-13 | 2017-12-29 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
| DK2558105T3 (da) | 2010-04-12 | 2020-01-27 | Reata Pharmaceuticals Inc | Bardoxolonmethyl til behandling af fedme |
| CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
| MX348862B (es) | 2011-03-11 | 2017-07-03 | Reata Pharmaceuticals Inc | Derivados c4-monometil triterpenoides y sus metodos de uso. |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法 |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| EP4736949A2 (en) | 2013-08-23 | 2026-05-06 | Reata Pharmaceuticals Holdings, LLC | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| US20170333450A1 (en) | 2014-10-31 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| EP3256451B1 (en) | 2015-02-12 | 2021-10-20 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| JP7074674B2 (ja) | 2015-09-23 | 2022-05-24 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体 |
| CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11427533B2 (en) | 2017-07-13 | 2022-08-30 | Pliva Hrvatska D.O.O. | Crystalline polymorphs of bardoxolone methyl |
| ES2967689T3 (es) | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| CN113164436A (zh) | 2018-11-27 | 2021-07-23 | 协和麒麟株式会社 | 药物组合物 |
| JP7714473B2 (ja) * | 2019-05-31 | 2025-07-29 | デナリ セラピューティクス インコーポレイテッド | ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法 |
| EP3999522B1 (en) | 2019-07-19 | 2025-09-03 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| BR112022022599A2 (pt) | 2020-05-09 | 2023-03-21 | Reata Pharmaceuticals Holdings Llc | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma |
| AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| SI2395979T1 (sl) | 2009-02-13 | 2017-12-29 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
-
2010
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en not_active Ceased
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008023A2 (pt) | forma de dosagem sólida | |
| BR112013014361A2 (pt) | forma de dosagem | |
| DK2427449T3 (da) | Vinylindazolylforbindelser | |
| BR112012006859A2 (pt) | compostos | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| EP2469625A4 (en) | OMNIBUS BAR | |
| EP2445547A4 (en) | CATHETERISM SYSTEM | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112010002728A5 (de) | Turboinhalator | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BR112012004964A2 (pt) | girocóptero | |
| EP2409976A4 (en) | GLYCINE TRANSPORTER INHIBITOR | |
| BR112012031102A2 (pt) | forma de dosagem oral sólida | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| BRPI0807882A2 (pt) | Forma de dosagem | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| DK2488157T3 (da) | Forbedrede formuleringer | |
| DE112010003255A5 (de) | Fördergutverteiler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US) |